Pharmaceutical Group Sues US Government Over Medicare Drug Pricing Rule
MT newswire2026/10/07 17:4301:43 PM EDT, 10/07/2026 (MT Newswires) -- The Pharmaceutical Research and Manufacturers of America said Wednesday it filed a lawsuit against the US government seeking to vacate Medicare's most favored nation drug pricing policy, alleging that it is unlawful and exceeds Centers for Medicare & Medicaid Services' authority. The complaint filed in the US District Court for the District of Columbia challenges the GLOBE rule, which requires drug manufacturers to pay rebates to the CMS that effectively limit Medicare Part B drug prices to benchmarks based on prices in 19 OECD countries, according to a statement. The group said the rule would provide minimal patient benefit, with only 0.3% of Medicare Part B beneficiaries expected to benefit from lower out-of-pocket costs, and could reduce investment in research and development. The group argued that the policy imposes nationwide price-setting policies without congressional authorization and raises constitutional concerns. The Department of Health and Human Services did not immediately respond to MT Newswires' request for comment. Price: 142.80, Change: +0.86, Percent Change: +0.61
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like

Bitcoin rebounds sharply from oversold levels, briefly surpassing $57,000

Masayoshi Son's Trillion-Dollar Gamble: Once Considered Acquiring SK Hynix
According to reports, Masayoshi Son once planned to acquire the South Korean memory chip giant SK Hynix for nearly 1 trillion US dollars and had approached Wall Street institutions to seek financing, but SoftBank has confirmed it is no longer actively pursuing the deal. The massive financing requirement and South Korean regulatory restrictions were major obstacles. This plan also highlights SoftBank’s further strategic intention to invest in AI storage chips.
"Sell-offs bring more sell-offs! Goldman Sachs predicts another large-scale sell-off in the U.S. stock market in the coming week."
Goldman Sachs stated that the bank’s “panic index” has risen to 9 out of 10, with systemic selling pressure continuing to spread. In the coming week, CTAs may sell up to $80.6 billion in US stocks, and even if the market remains flat, there is still $65.8 billion in sell orders waiting to be executed. The Anthropic IPO failed to boost market risk appetite, and concerns over AI investment returns continue to weigh on tech stock valuations.